Daniel W. Burgess
FRQA, Chief Compliance Officer, Pharm-Olam, Houston, TX, USA
Mr. Burgess holds a bachelor’s degree from the University of South Wales, UK and further qualifications in ISO, audit and instructional design. A graduate from the initial cohort of the RQA Diploma in Research Quality Assurance, he is recognized by his peers as a Fellow in Research Quality Assurance. A speaker and tutor for a number of international quality associations and serves on the editorial board of Policy
& Medicine Compliance Update (formerly LSCU) and as a member of the Pharm-Olam board. An advocate of continuous improvement and transparency, Mr. Burgess is regarded as an innovator, expert and thought leader in practical process improvement and achievement through visual measurement, bringing a unique approach to 'living' quality. Dan is currently innovating to build risk management thinking into the core of Pharm-Olam, driving continuous improvement and bringing over 30 years of experience and teamwork to the through quality assurance, auditing, quality control, training, data privacy and compliance. His experience includes progressive leadership roles within several leading pharmaceutical industry organizations including Ipsen, Novartis, Alexion, Thermo Fisher Scientific and Pfizer. Bringing a deep understanding in the creation of quality strategies for continuous improvement which improve the lives of customers and add value to stakeholders: Envisioning and implementing effective quality and compliance programs in support of business processes, building unique training for global auditing teams and the management of inspection readiness; Enabling transparent communication and providing leadership with demonstrated ability to move sites from unacceptable to acceptable status.